Skip to main content

Table 1 Summary of Model Parameters (including uncertainty at 95% confidence intervals)

From: Cost-effectiveness analysis of doctor-pharmacist collaborative prescribing for venous thromboembolism in high risk surgical patients

Parameter

Value

Source

Mean number of patients in PAC per year (from 2009 to 2013)

5688

[11]

Number of patients at high risk of VTE

3583

[11]

Annual cost of new model of care

Model 1 (existing pharmacy service)

$20,989

[11, 17]

Annual cost of new model of care

Model 2 (new pharmacy service)

$154,579 - $12,741 = $141,838

[11, 17]

Appropriateness of VTE prophylaxis new model of care (%)

100 (SE 0.01)

[11]

Appropriateness of VTE prophylaxis usual care (%)

91.1 (84.7–97.3)

[11]

Probability of DVT with appropriate prophylaxis (%)

1.6 (0.9–2.3)

[11]

Probability of DVT with inappropriate prophylaxis (%)

4.0 (2.7–5.3)

[11]

Probability of PE with appropriate prophylaxis (%)

1.1 (0.7–1.5)

[11]

Probability of PE with inappropriate prophylaxis (%)

2.7 (1.9–3.3)

[11]

Probability of 12 months mortality post DVT (%)

14.6 (14.0–15.2)

[11]

Probability of 12 month mortality post PE (%)

52.3 (51.5–53.1)

[11]

Probability of 30 day mortality post DVT (%)

5.5 (5.1–5.9)

[11]

Probability of 30 day mortality post PE (%)

44.4 (43.6–45.2)

[11]

Direct cost to healthcare system of one episode of acute DVT

$10,077

[2]

Direct cost to healthcare system of one episode of acute PE

$10,042

[2]

QALYs lost post-acute episode of DVT

0.02 (0.01–0.04)

[16]

QALYs lost post-acute episode of PE

0.02 (0.01–0.05)

[16]

QALYs lost post-acute episode of DVT + 30 day death

0.0675 ()

[16]

QALYs lost post-acute episode of PE + 30 day death

0.0625 ()

[16]